These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7699234)

  • 41. A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B.
    Kagawa T; Morizane T; Saito H; Tsunematsu S; Tada S; Kumagai N; Tsuchimoto K; Sugiura H; Mukai M; Tsuchiya M
    Am J Gastroenterol; 1993 Feb; 88(2):212-6. PubMed ID: 8424423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
    Wong DK; Cheung AM; O'Rourke K; Naylor CD; Detsky AS; Heathcote J
    Ann Intern Med; 1993 Aug; 119(4):312-23. PubMed ID: 8328741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].
    Zhu SS; Dong Y; Xu ZQ; Wang LM; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang HF
    Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):738-743. PubMed ID: 27938558
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.
    Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T
    Hepatology; 1994 Aug; 20(2):287-90. PubMed ID: 8045488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liver function and hepatitis markers in carriers of hepatitis B virus in New Zealand.
    Hopkirk N; Moyes CD; Lucas CR
    N Z Med J; 2000 Apr; 113(1107):114-6. PubMed ID: 10834277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha.
    Brunetto MR; Oliveri F; Colombatto P; Capalbo M; Barbera C; Bonino F
    J Hepatol; 1995; 22(1 Suppl):42-4. PubMed ID: 7602075
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province].
    Zhang BF; Cheng ML; Zhang Q; Zhao XK; Yu L; Yang J; Deng KS; Zhang LS; Wang J; Hu YX
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):945-950. PubMed ID: 30669789
    [No Abstract]   [Full Text] [Related]  

  • 51. Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.
    Ma Q; Qin B; Gong X; Lu X
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):820-4. PubMed ID: 23411867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 54. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.
    Alexander GJ; Brahm J; Fagan EA; Smith HM; Daniels HM; Eddleston AL; Williams R
    Lancet; 1987 Jul; 2(8550):66-9. PubMed ID: 2885573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomised controlled trial of recombinant human interferon -alpha A for chronic active hepatitis B.
    Williams SJ; Craig PI; Cooksley WG; Bye WA; Bilous M; Grierson JM; Nightingale BN; Burnett L; Hensley WJ; Batey RG
    Aust N Z J Med; 1990 Feb; 20(1):9-19. PubMed ID: 2181991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
    Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
    J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.